Abstract
T-cell zeta chain expression, phosphorylation and degradation and their role in T-cell signal transduction and immune response regulation in health and disease. Zeta chain is a stable constituent of the antigen specific T-cell receptor and its phosphorylation is one of the earliest and key events in the T-cell signal transduction. Zeta chain phosphorylation is strictly controlled by the action of sarcomafamily kinases and also by phosphatases, indicating its crucial role in antigen specific T-cell activation. Furthermore, after its phosphorylation and T-cell activation, ζ-chain is ubiquitylated and degraded, a fact suggesting that its level on T-cell surface is also under control and contribute to the regulation of an initiated immune response. Zeta chain expression and/or phosphorylation seems to be of great importance in many clinical conditions from the pathogenesis of various types of cancer to the immunosuppressive state in dialysis patients. Its levels are also affected by chronic inflammation. In addition to its role in the antigen specific signal transduction, ζ-chain is present only in T-cells and natural killer cells, making it a possible target for immunotherapeutic applications. The recent discovery of specific inhibitors of ζ-chain phosphorylation opens new horizons for future research and for possible therapeutic interventions in various clinical conditions.
Keywords: T-cell receptor, zeta chain, cancer, autoimmune disease, infection, inflammation
Current Signal Transduction Therapy
Title: T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Volume: 1 Issue: 2
Author(s): Theodoros Eleftheriadis, Georgia Antoniadi, Vassilios Liakopoulos and Alexandros Kortsaris
Affiliation:
Keywords: T-cell receptor, zeta chain, cancer, autoimmune disease, infection, inflammation
Abstract: T-cell zeta chain expression, phosphorylation and degradation and their role in T-cell signal transduction and immune response regulation in health and disease. Zeta chain is a stable constituent of the antigen specific T-cell receptor and its phosphorylation is one of the earliest and key events in the T-cell signal transduction. Zeta chain phosphorylation is strictly controlled by the action of sarcomafamily kinases and also by phosphatases, indicating its crucial role in antigen specific T-cell activation. Furthermore, after its phosphorylation and T-cell activation, ζ-chain is ubiquitylated and degraded, a fact suggesting that its level on T-cell surface is also under control and contribute to the regulation of an initiated immune response. Zeta chain expression and/or phosphorylation seems to be of great importance in many clinical conditions from the pathogenesis of various types of cancer to the immunosuppressive state in dialysis patients. Its levels are also affected by chronic inflammation. In addition to its role in the antigen specific signal transduction, ζ-chain is present only in T-cells and natural killer cells, making it a possible target for immunotherapeutic applications. The recent discovery of specific inhibitors of ζ-chain phosphorylation opens new horizons for future research and for possible therapeutic interventions in various clinical conditions.
Export Options
About this article
Cite this article as:
Eleftheriadis Theodoros, Antoniadi Georgia, Liakopoulos Vassilios and Kortsaris Alexandros, T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012039
DOI https://dx.doi.org/10.2174/157436206777012039 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center
Reviews on Recent Clinical Trials Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology The Role of the Healthy Dietary Intake in Women with Human Papilloma Virus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Recent Studies and Biological Aspects of Substantial Indole Derivatives with Anti-cancer Activity
Current Organic Chemistry Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry